Plus   Neg

Sealed Air Boosts FY19 Outlook - Quick Facts

While reporting financial results for the second quarter, Sealed Air Corp. (SEE) on Friday raised its adjusted earnings and net sales guidance for the full-year 2019. The company's outlook includes a five-month contribution from the APS acquisition.

For fiscal 2019, the company now expects adjusted earnings in the range of $2.70 to $2.80 per share, including $0.07 dilution from the APS acquisition. This is up from the previously provided guidance range of $2.65 to $2.75 per share.

The company also now expects net sales of about $4.85 billion, up from the previously provided sales guidance of $4.8 billion. The company continues to expect currency to have an unfavorable impact of approximately $130 million on net sales.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.73 per share on net sales of $4.80 billion for the year. Analysts' estimates typically exclude special items.

In addition, the company on Thursday completed the acquisition of Automated Packaging Systems, Inc. (APS), a leading manufacturer of automated bagging systems (including the iconic Autobag brand), for $510 million on a cash and debt free basis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT